I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem […]
Interview with Bioheart CSO, Kristin Comella including on FDA Read More »
Remember that old TV show the Odd Couple with very proper Felix Unger and his polar opposite Oscar Madison who has all kinds of baggage? They’ve cloned it into a remake to be on TV soon here in the US in 2015. It seems only fitting then that actual human cloning research has a new
The Odd Couple of Cloning Research: Mitalipov & Woo Suk Hwang Unite Read More »
I invited Nobel Laureate Shinya Yamanaka to do an interview on the future of clinical translation of induced pluripotent stem cells (iPSC). He provides some intriguing new insights into the iPSC field and the broader stem cell arena. PK: The Takahashi Team’s active Clinical Study using iPSCs to make RPEs to treat Macular Degeneration has
Shinya Yamanaka Interview on Clinical Use of IPSC Read More »
The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related
Advanced Cell Technology pub: Trial for Macular Degeneration Read More »
PostDoc Job Opening UC Davis School of Medicine An NIH and CIRM-funded postdoctoral fellow position in the Knoepfler Lab at UC Davis School of Medicine is open. The focus of research will be on the epigenomic and chromatin regulatory factors in human iPS cells and ES cells as well as cancer cells. Applicants must have a PhD,
Postdoc Job Opening at UC Davis School of Medicine Read More »
The Knoepfler Lab conducts stem and cancer cell as well as chromatin/epigenetics research at the UC Davis School of Medicine. Our team has two big picture goals: (1) catalyzing the development of more effective treatments for cancers based on targeting stem cell-related machinery in tumorigenesis and (2) producing safer stem cell-based regenerative medicine therapies. We are particularly
Was Einstein wrong on his definition of insanity? “Insanity”, said Einstein, “is doing the same thing over and over again and expecting different results.” But in science, how sane is it to expect experiments to give precisely the same results? How big a problem is irreproducibility in science? Experiments on that question have given variable
Was Einstein Wrong About Insanity? Read More »
By Dr. Susan Lim A record 4100 delegates attended the 11th Annual Meeting of the International Society for Stem Cell Research (ISSCR), held at the Convention and Exhibition Center in Boston from 12-15 June 2013. Co-sponsored by the Harvard Stem Cell Institute, the Meeting featured 7 Plenary sessions including a Presidential Symposium, 20 concurrent scientific
Delightful overview of ISSCR 2013 by guest blogger Dr. Susan Lim Read More »
One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS
Interview with Gary Rabin of Advanced Cell Technology (ACT) Read More »
When are iPS cell-based therapies ready to be tested in actual people? It’s the million or perhaps even billion dollar question of today in the stem cell field. I realize that perhaps it is also a dangerous question, politically-speaking, for me to ask in a public forum, but patient lives as well as potentially the